A dose of 30–300 mg/kg CXL in rats hasanti-inflammatory effects without producing significant ulcerogeniceffects. We speculate that the findingswe describe here could provide a novel breakthrough for the treatmentof autoimmune diseases driven by the modulation of STING activity.Should CXL itself not prove to be useful in a clinical setting, itcould serve as a lead compound for further optimization. Here, STING1 is linked to autoimmune disease.